Title |
Molecular Biomarkers for the Evaluation of Colorectal Cancer Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology
|
---|---|
Published in |
The Journal of Molecular Diagnostics, February 2017
|
DOI | 10.1016/j.jmoldx.2016.11.001 |
Pubmed ID | |
Authors |
Antonia R. Sepulveda, Stanley R. Hamilton, Carmen J. Allegra, Wayne Grody, Allison M. Cushman-Vokoun, William K. Funkhouser, Scott E. Kopetz, Christopher Lieu, Noralane M. Lindor, Bruce D. Minsky, Federico A. Monzon, Daniel J. Sargent, Veena M. Singh, Joseph Willis, Jennifer Clark, Carol Colasacco, R. Bryan Rumble, Robyn Temple-Smolkin, Christina B. Ventura, Jan A. Nowak |
Abstract |
To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Twenty-one guideline statements were established. Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented. Key Words: Molecular diagnostics; Gastrointestinal; Histology; Genetics; Oncology. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 33 | 33% |
Spain | 6 | 6% |
Brazil | 4 | 4% |
United Kingdom | 3 | 3% |
Australia | 3 | 3% |
Canada | 3 | 3% |
Mexico | 2 | 2% |
Turkey | 2 | 2% |
Ecuador | 2 | 2% |
Other | 11 | 11% |
Unknown | 31 | 31% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 53 | 53% |
Scientists | 24 | 24% |
Practitioners (doctors, other healthcare professionals) | 20 | 20% |
Science communicators (journalists, bloggers, editors) | 3 | 3% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 133 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 19 | 14% |
Other | 14 | 11% |
Student > Master | 14 | 11% |
Student > Bachelor | 12 | 9% |
Student > Postgraduate | 12 | 9% |
Other | 26 | 20% |
Unknown | 36 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 41 | 31% |
Biochemistry, Genetics and Molecular Biology | 24 | 18% |
Agricultural and Biological Sciences | 7 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
Nursing and Health Professions | 4 | 3% |
Other | 13 | 10% |
Unknown | 39 | 29% |